Israel - English - Ministry of Health

astrazeneca (israel) ltd - osimertinib as mesylate - tablets - osimertinib as mesylate 80 mg - osimertinib - tagrisso as monotherapy is indicated for: • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) mutations. • the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclctagrisso is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol - film coated tablets - dapagliflozin propanediol 12.30 mg/dose - dapagliflozin - forxiga is indicated:- in adults aged 18 years and older for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise •as monotherapy when metformin is considered inappropriate due to intolerance. •in addition to other medicinal products for the treatment of type 2 diabetes. - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (nyha class ii-iv) with reduced ejection fraction- to reduce the risk of sustained egfr decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. limitations of use -forxiga is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. forxiga is not expected to be effective in these populations.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol - film coated tablets - dapagliflozin propanediol 6.150 mg/dose - dapagliflozin - forxiga is indicated:- in adults aged 18 years and older for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise •as monotherapy when metformin is considered inappropriate due to intolerance. •in addition to other medicinal products for the treatment of type 2 diabetes. - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (nyha class ii-iv) with reduced ejection fraction- to reduce the risk of sustained egfr decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. limitations of use -forxiga is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. forxiga is not expected to be effective in these populations.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - astragalus propinquus root (unii: 922op8yupf) (astragalus propinquus root - unii:922op8yupf) - astragalus propinquus root 3 [hp_x] in 1 ml - directions: for oral use. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - astragalus propinquus root (unii: 922op8yupf) (astragalus propinquus root - unii:922op8yupf) - astragalus propinquus root 2 [hp_x] in 1 ml - directions: for oral use only. use: temporary relief of headache.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - astragalus propinquus root (unii: 922op8yupf) (astragalus propinquus root - unii:922op8yupf), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw) - astragalus propinquus root 3 [hp_x] in 1 ml - directions: for oral use only. use: temporary relief of headache.

Israel - English - Ministry of Health

astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers.vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Israel - English - Ministry of Health

astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers. vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Israel - English - Ministry of Health

astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers. vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Israel - English - Ministry of Health

astra zeneca israel ltd - vandetanib 100 mg - film coated tablets - vandetanib - caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (mtc) in patients with unresectable locally advanced or metastatic disease. for patients in whom rearranged during transfection (ret) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision